SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation C23S

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 5-HT2AR: 5HT2CR Balance in Brain Connectivity in Cocaine Dependence

This project will evaluate the role of the 5-HT2CR:5-HT2AR balance in impulsive action and cue reactivity in cocaine-dependent subjects as compared to non-drug using controls.

NCT03921151 Cocaine Dependence Drug: Mirtazapine 15 MG Oral Tablet Other: Placebo oral capsule
MeSH:Cocaine-Related Disorders

Change in Interaction of the serotonin receptor (5-HTR) type-2C Cys23Ser single nucleotide polymorphism (SNP) and a 5-HT2AR antagonist on the functional circuitry underlying impulsive action.. Change in fMRI activation during Go/NoGo (impulsivity) task with placebo dose vs Mirtazapine dose. --- Cys23Ser ---

Change in Interaction of the 5-HT2CR Cys23Ser SNP and a 5-HT2AR antagonist on the functional circuitry underlying cue reactivity. --- Cys23Ser ---

Brain and behavioral responses to the 5-HT2AR blocking medication mirtazapine will be compared between subjects who have high and low functioning of the 5-HT2CR based on presence of a specific, functionally-relevant single nucleotide polymorphism (SNP) of the 5-HT2CR (Cys23Ser). --- Cys23Ser ---

The 5-HT2CR Cys23Ser SNP is thought to decrease the function of the protein and a preliminary observation indicates cocaine-dependent subjects carrying the CC genotype (Ser23 protein variant) display significantly higher cue reactivity. --- Cys23Ser ---

Primary Outcomes

Description: Change in fMRI activation during Go/NoGo (impulsivity) task with placebo dose vs Mirtazapine dose

Measure: Change in Interaction of the serotonin receptor (5-HTR) type-2C Cys23Ser single nucleotide polymorphism (SNP) and a 5-HT2AR antagonist on the functional circuitry underlying impulsive action.

Time: Baseline to 1 week

Secondary Outcomes

Description: Change in fMRI activation during Attentional bias task with placebo dose vs Mirtazapine dose

Measure: Change in Interaction of the 5-HT2CR Cys23Ser SNP and a 5-HT2AR antagonist on the functional circuitry underlying cue reactivity

Time: Baseline to 1 week

Other Outcomes

Description: Change in Impulsivity as measured by Go/NoGo task with placebo dose vs Mirtazapine dose

Measure: Change in Effective connectivity involved in the 5-HT2AR:5-HT2CR homeostasis impulsive action

Time: Baseline to 1 week

Description: Change in Cue reactivity as measured by Attentional bias task with placebo dose vs Mirtazapine dose

Measure: Change in Effective connectivity involved in the 5-HT2AR:5-HT2CR homeostasis cue reactivity

Time: Baseline to 1 week

Description: Change in fMRI activation with other 5-HT2CR SNPs during Attentional bias task with placebo dose vs Mirtazapine dose

Measure: Change in Explore interactions between other 5-HT2CR SNPs and brain activation during attentional bias task after a 5- HT2AR antagonist

Time: Baseline to 1 week

Description: Change in fMRI activation with other 5-HT2CR SNPs during Go/NoGo (impulsivity) task with placebo dose vs Mirtazapine dose

Measure: Change in Explore interactions between other 5-HT2CR SNPs and brain activation during Go/NoGo (impulsivity) task after a 5- HT2AR antagonist

Time: Baseline to 1 week


HPO Nodes